Today’s Research Reports on Cardiome Pharma, IntelliPharmaCeutics International, Nuvo Pharmaceuticals and Oncolytics Biotech Inc.
NEW YORK, NY / ACCESSWIRE / November 9, 2017 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.
RDI has Initiated Coverage Today on:
Cardiome Pharma Corp.
https://rdinvesting.com/news/?ticker=COM.TO
IntelliPharmaCeutics International Inc.
https://rdinvesting.com/news/?ticker=IPCI.TO
Nuvo Pharmaceuticals Inc.
https://rdinvesting.com/news/?ticker=NRI.TO
Oncolytics Biotech Inc.
https://rdinvesting.com/news/?ticker=ONC.TO
Cardiome Pharma Corp.'s stock moved 5.00% lower Wednesday, to close the day at $1.90. The stock recorded a trading volume of 27,683 shares, which was above its three months average volume of 24,381 shares. In the last year, Cardiome Pharma Corp.'s shares have traded in a range of 1.64 - 6.06. The share price has gained 15.85% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $2.34 is below its 200-day moving average of $4.18. Shares of Cardiome Pharma have fallen approximately 49.33 percent year-to-date.
Access RDI's Cardiome Pharma Corp. Research Report at:
https://rdinvesting.com/news/?ticker=COM.TO
On Wednesday, shares in IntelliPharmaCeutics International Inc. recorded a trading volume of 15,955 shares, which was below the three months average volume of 18,937 shares. The stock ended the day 3.45% higher at 1.20. The share price has gained 20.00% from its 52-week low with a 52-week trading range of 1.00 - 4.50.The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $1.25 is below its 200-day moving average of $2.06. Shares of IntelliPharmaCeutics International have fallen approximately 68.34 percent year-to-date.
Access RDI's IntelliPharmaCeutics International Inc. Research Report at:
https://rdinvesting.com/news/?ticker=IPCI.TO
Nuvo Pharmaceuticals Inc.'s stock edged 0.75% lower Wednesday, to close the day at $3.98. The stock recorded a trading volume of 4,237 shares, which was below its three months average volume of 9,740 shares. In the last year, Nuvo Pharmaceuticals Inc.'s shares have traded in a range of 3.76 - 6.43. The stock is currently trading 38.10% below its 52-week high. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $4.17 is below its 200-day moving average of $4.31. Shares of Nuvo Pharmaceuticals Inc. are trading at a Price to Earnings ratio of 9.21. Shares of Nuvo Pharmaceuticals have fallen approximately 29.56 percent year-to-date.
Access RDI's Nuvo Pharmaceuticals Inc. Research Report at:
https://rdinvesting.com/news/?ticker=NRI.TO
On Wednesday, shares in Oncolytics Biotech Inc. recorded a trading volume of 628,823 shares, which was above the three months average volume of 148,015 shares. The stock ended the day 12.28% higher at 0.64. The share price has gained 236.84% from its 52-week low with a 52-week trading range of 0.19 - 1.13.The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $0.61 is greater than its 200-day moving average of $0.60. Shares of Oncolytics Biotech have gained approximately 141.51 percent year-to-date.
Access RDI's Oncolytics Biotech Inc. Research Report at:
https://rdinvesting.com/news/?ticker=ONC.TO
Our Actionable Research on Cardiome Pharma Corp. (TSX:COM.TO), IntelliPharmaCeutics International Inc. (TSX:IPCI.TO), Nuvo Pharmaceuticals Inc. (TSX:NRI.TO) and Oncolytics Biotech Inc. (TSX:ONC.TO) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com